Država: Irska
Jezik: engleski
Izvor: HPRA (Health Products Regulatory Authority)
RANITIDINE HYDROCHLORIDE
PCO Manufacturing
150 Milligram
Tablets
1995-05-30
PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Zantac 150 mg Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 150mg ranitidine (as hydrochloride). For full list of excipients, _see section 6.1._ 3 PHARMACEUTICAL FORM Film-coated tablet. _Product imported from Belgium, Greece, the Netherlands and the UK:_ White, round, biconvex tablets, engraved ‘GXEC2’ on one side plain on the other. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS In the treatment of duodenal ulcer and benign gastric ulcer, including that associated with non-Steroidal anti- inflammatory agents. Prevention of non-Steroidal anti-inflammatory drug (including aspirin) associated duodenal ulcers, especially in patients with a history of peptic ulcer disease. Zantac tablets are also indicated for treatment of post-operative ulcer, reflux oesophagitis, Zoilinger-Ellison syndrome and other conditions where reduction of gastric acid secretion is likely to be beneficial. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION _Adults only:_ The usual initial dosage in duodenal or benign gastric ulcer is 150 mg twice daily or 300 mg at night. This may be increased to ranitidine 300 mg twice daily without an increased incidence of unwanted effects. Subsequently a maintenance dose of 150mg at night may be used. Smoking is associated with a higher rate of ulcer relapse and such patients should be advised to stop smoking. In those who fail to comply with such advice, a dose of 300mg at night provides additional therapeutic benefit over the standard dose. In most cases of duodenal ulcer, benign gastric ulcer and post operative ulcer, healing occurs within 4 weeks. Healing usually occurs after a further 4 weeks in those not fully healed after the initial 4 weeks. In Pročitajte cijeli dokument